CompletedPHASE1, PHASE2NCT03001310
Gene Therapy for Achromatopsia (CNGB3)
Studying Achromatopsia
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- MeiraGTx UK II Ltd
- Principal Investigator
- James Bainbridge, ProfChief Investigator
- Intervention
- AAV - CNGB3(biological)
- Enrollment
- 23 enrolled
- Eligibility
- 3 years · All sexes
- Timeline
- 2017 – 2019
Study locations (2)
- University of Michigan Kellog Eye Centre, Ann Arbor, Michigan, United States
- Moorfields Eye Hospital NHS Foundation Trust, London, United Kingdom
Collaborators
Janssen Research & Development, LLC
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT03001310 on ClinicalTrials.govOther trials for Achromatopsia
Additional recruiting or active studies for the same condition.
- RECRUITINGNCT07085533Natural History Study of Inherited Retinal DiseasesZhongmou Therapeutics
- ACTIVE NOT RECRUITINGPHASE1, PHASE2NCT02935517Safety and Efficacy Trial of AAV Gene Therapy in Patients With CNGA3 Achromatopsia (A Clarity Clinical Trial)Beacon Therapeutics
- ACTIVE NOT RECRUITINGPHASE1, PHASE2NCT02599922Safety and Efficacy Trial of AAV Gene Therapy in Patients With CNGB3 Achromatopsia (A Clarity Clinical Trial)Beacon Therapeutics
- ACTIVE NOT RECRUITINGPHASE1, PHASE2NCT02610582Safety and Efficacy of rAAV.hCNGA3 Gene Therapy in Patients With CNGA3-linked AchromatopsiaSTZ eyetrial